With Dexcom G7, real-time glucose readings are sent automatically to a compatible display device. Credit: Business Wire / Dexcom.

DexCom has obtained CE Mark for its G7 continuous glucose monitoring (CGM) system designed for people with diabetes.

Developed in partnership with Verily, the new Dexcom G7 CGM system is indicated for diabetes patients aged two years and above, including pregnant women, in Europe.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The next-generation CGM system allows people to manage their diabetes using a small, all-in-one wearable sensor along with a redesigned, simplified mobile app that provides Dexcom Clarity integration.

Said to be faster than any other CGM on the market, the sensor warms up in 30 minutes and sends real-time glucose readings to a compatible smart device or receiver automatically.

Additionally, the system offers a set of customisable alerts that can warn users regarding high or low glucose levels.  

The company stated that the remote monitoring and reporting capabilities will enable users to stay connected with care teams.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Dexcom chairman, president and CEO Kevin Sayer said: “This all-new platform offers an incredibly powerful CGM that is simple to use, providing our users with insightful glucose data on one screen that helps them spend less time managing diabetes and more time doing the things they love. Dexcom G7 takes everything people love about G6 and makes it even better.”

The company said that it is also working with insulin pump partners to integrate the new system into existing and future automated insulin delivery systems.

It expects to launch the Dexcom G7 CGM system in Europe in the next few weeks, with plans to also introduce an updated CGM algorithm later in the year.